Signals flagged in the original
Analyzed by our bias model Full breakdown ↓
The FDA has initiated a safety review of mifepristone, a drug used for abortions, following pressure from anti-abortion advocates. The review is expected to take about six months and may not conclude before the midterm elections. The FDA previously removed in-person screening requirements for the drug, which has increased access to medication abortions.
Our neutral summary
The FDA has initiated a safety review of mifepristone, a drug used for abortions, following pressure from anti-abortion advocates. The review is expected to take about six months and may not conclude before the midterm elections. The FDA previously removed in-person screening requirements for the drug, which has increased access to medication abortions.
The reporting belongs to Washington Examiner; we don't reproduce it.
No note attached
on this article.
FDA launches mifepristone study after pressure from Trump’s right flank
FDA Initiates Safety Review of Mifepristone Amid Regulatory Pressure